Figure 2

Clearance and recurrence plot of the infections observed in the in vivo therapeutic efficacy study. Of the 125 subjects enrolled in this study 107 completed the 28-day follow up. An absence of fever within 48 hours (Day 2) was observed for all 107 subjects completing the study. Eighty-eight (82.2%) subjects were aparasitaemic for both sexual and asexual morphological stages by Day 2 and 17 (15.9%) by Day 7 (Primary infection, red line). Two (1.9%) subjects remained positive for sexual stage parasites until a time between Day 7 and Day 14, at which point no parasites remained detectable by microscopy (Primary infection, red line). Of these 107 subjects, 17 subjects were parasite positive at a time point beyond the 28-day enrollment period, ranging from 44-148 days post-enrollment (Recurrent infection, blue line).